Home The Word Brain	My Amedeo FAQ Privacy About
	Hanzi Hunter Learning 500 Chinese characters in 30 days is possible. Abstract • About

Breast Cancer

Free Subscription 02.03.2026 1 Acta Cytol 1 Am J Clin Oncol 1 Am J Clin Pathol 1 Am J Pathol 10 Ann Surg Oncol 1 Anticancer Res 3 BMC Cancer 1 Br J Cancer 2 Breast Cancer 5 Breast Cancer (Dove Med Press) 5 Breast Cancer Res 6 Breast Cancer Res Treat 2 Breast J 2 Cancer 3 Cancer Lett 2 Clin Breast Cancer 1 Eur J Surg Oncol 1 Histopathology 1 Int J Cancer 1 Int J Radiat Oncol Biol Phys 1 J Natl Cancer Inst 1 Lancet 1 N Engl J Med 5 NPJ Breast Cancer 1 PLoS One 1 Radiology 2 Radiother Oncol 1 Semin Oncol

Retrieve available abstracts of this week’s articles: HTML format

Single Articles

Acta Cytol

1. UZUN E, Erkilic S
   The Utility Of The Thinprep(R) For Determining Hormone Receptor And Her2 Status In Axillary Lymph Node Fine Needle Aspiration In Metastatic Breast Cancer; Comparison With The Primary Tumor.
   Acta Cytol. 2026 Feb 23:1-23. doi: 10.1159/000551115.
   PubMed         Abstract available
   
   

   
   Am J Clin Oncol

2. LI E, Spierling Bagsic SR, Belasco RF, Nguyen CH, et al
   Trends in Neoadjuvant Pembrolizumab Use in Triple-Negative Breast Cancer.
   Am J Clin Oncol. 2026 Feb 24. doi: 10.1097/COC.0000000000001305.
   PubMed         Abstract available
   
   

   
   Am J Clin Pathol

3. JEROME JA, Vanderschelden R, Clark BZ, Yu J, et al
   Magee Equation 3 demonstrates predictive and prognostic value for neoadjuvant chemotherapy outcomes in estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer.
   Am J Clin Pathol. 2026;165:aqag001.
   PubMed         Abstract available
   
   

   
   Am J Pathol

4. JONES D
   Advancing Breast Cancer Management Through an Enhanced Understanding of Disease Heterogeneity from Initiation to Metastasis.
   Am J Pathol. 2025;195:1967-1971.
   PubMed        
   
   

   
   Ann Surg Oncol

5. YEE GN, Hwang S, Wilke LG, Freedman LM, et al
   Commission on Cancer Quality Measure for Omission of Sentinel Lymph Node Biopsy (SNB) in Women Age 70 or Older with Hormone Receptor-Positive (HR+) Invasive Breast Cancer (IBC) Undergoing Breast-Conserving Surgery (BCS): Review of Historical Performan
   Ann Surg Oncol. 2026 Feb 21. doi: 10.1245/s10434-026-19222.
   PubMed         Abstract available
   
   
6. KASSI A, Rodriguez L, Wu R, Ishikawa T, et al
   ASO Author Reflections: PARP7 Association to Estrogen and Immunity in Clinical Breast Cancer.
   Ann Surg Oncol. 2026 Feb 21. doi: 10.1245/s10434-026-19296.
   PubMed        
   
   
7. HANNOUN-LEVI JM
   ASO Author Reflections: Breast Cancer Local Recurrence: True Recurrence or New Primary?
   Ann Surg Oncol. 2026 Feb 22. doi: 10.1245/s10434-026-19297.
   PubMed        
   
   
8. DIMAANO K, Castillo O Jr, Moazzez A, Ozao-Choy J, et al
   Examining the Representation of Minority Race and Ethnicity Groups in Breast Cancer Clinical Trials in the USA Published 2012-2022.
   Ann Surg Oncol. 2026 Feb 23. doi: 10.1245/s10434-026-19214.
   PubMed         Abstract available
   
   
9. PAN Y, Duan C, Du J, Zhang J, et al
   ASO Visual Abstract: St. Gallen International Breast Cancer Consensus-Based Clinical Decision Validation: Concordance Assessment Between Deep Large Language Model Outputs and Global Expert Panel Recommendations.
   Ann Surg Oncol. 2026 Feb 24. doi: 10.1245/s10434-026-19319.
   PubMed        
   
   
10. JACINTO AI, Keegan THM, Li Q, Maguire FB, et al
    ASO Visual Abstract: Differences in Treatment and Survival for Secondary Triple Negative Breast Cancer in Premenopausal Women.
    Ann Surg Oncol. 2026 Feb 24. doi: 10.1245/s10434-026-19126.
    PubMed        
    
    
11. PAN Y, Zhu L
    ASO Author Reflections: Large Language Models in Breast Cancer Decision-Making: Lessons from the St. Gallen International Breast Cancer Consensus.
    Ann Surg Oncol. 2026 Feb 24. doi: 10.1245/s10434-026-19330.
    PubMed        
    
    
12. KUEMMEL S, Fasching PA, Schmid P, Harbeck N, et al
    Surgical Outcomes After Neoadjuvant Pembrolizumab Plus Chemotherapy for Triple-Negative Breast Cancer: Results from the Randomized, Placebo-Controlled Phase 3 KEYNOTE-522 Study.
    Ann Surg Oncol. 2026 Feb 25. doi: 10.1245/s10434-026-19121.
    PubMed         Abstract available
    
    
13. SIDHU AS, Chopra AA, Bisch EJ, Chopra A, et al
    Psychosocial Morbidity in Patients with Breast Cancer Related Lymphedema: An Evaluation of Mental Health Diagnoses in Breast Cancer Survivors.
    Ann Surg Oncol. 2026 Feb 25. doi: 10.1245/s10434-026-19345.
    PubMed        
    
    
14. JIANG X, Huang Z, Cao Y, Ding J, et al
    ASO Author Reflections: Toward Personalized Neoadjuvant Therapy in HER2-Positive Breast Cancer-A Clinically Actionable Predictive Model.
    Ann Surg Oncol. 2026 Feb 27. doi: 10.1245/s10434-026-19295.
    PubMed        
    
    

    
    Anticancer Res

15. KAI A, Sasada S, Amioka AI, Shigematsu H, et al
    Prognostic Value of Metabolic Parameters on Dedicated Breast Positron Emission Tomography in Luminal Breast Cancer.
    Anticancer Res. 2026;46:1677-1684.
    PubMed         Abstract available
    
    

    
    BMC Cancer

16. TANG X, Wang T, Shi H, Zhang M, et al
    Breast cancer detection using microscopic images based on composition features.
    BMC Cancer. 2026 Feb 23. doi: 10.1186/s12885-025-15456.
    PubMed        
    
    
17. FAN Y, Sahoo S, Jolly MK, George JT, et al
    Regulatory network and spatial modeling reveal cooperative mechanisms of resistance and immune escape in ER+ breast cancer.
    BMC Cancer. 2026 Feb 23. doi: 10.1186/s12885-026-15691.
    PubMed        
    
    
18. UGUZTEMUR E, Dogan M
    Tumor-Infiltrating lymphocyte dynamics as biomarkers of neoadjuvant treatment response in luminal breast cancer.
    BMC Cancer. 2026 Feb 27. doi: 10.1186/s12885-026-15795.
    PubMed        
    
    

    
    Br J Cancer

19. KYE YH, Moon SJ, Cha HR, Kim TH, et al
    ASH2L induces tamoxifen resistance via H3K4me3 dependent ITGA6/ERK signaling in ER-positive breast cancer.
    Br J Cancer. 2026 Feb 24. doi: 10.1038/s41416-026-03347.
    PubMed         Abstract available
    
    

    
    Breast Cancer

20. KANAOKA H, Nagahashi M, Tsuchida J, Kuroiwa M, et al
    Prognostic significance of peripheral myeloid-derived suppressor cells in advanced breast cancer.
    Breast Cancer. 2026 Feb 23. doi: 10.1007/s12282-026-01831.
    PubMed        
    
    
21. NOZAKI F, Nakanishi Y, Hirotani Y, Kobayashi H, et al
    PIK3CA mutation in ER-negative and HER2-positive breast cancer with apocrine differentiation.
    Breast Cancer. 2026 Feb 23. doi: 10.1007/s12282-026-01837.
    PubMed         Abstract available
    
    

    
    Breast Cancer (Dove Med Press)

22. ALFARAFISA NM, Herriyanto RI, Alhaq KF, Fauzi MB, et al
    The Role of Actin-Binding Proteins in Breast Cancer Progression.
    Breast Cancer (Dove Med Press). 2026;18:566309.
    PubMed         Abstract available
    
    
23. OBEAGU EI
    Novel Microbiome-Driven Approaches to Counteract Chemotherapy-Induced Mucositis in Breast Cancer Patients.
    Breast Cancer (Dove Med Press). 2026;18:590718.
    PubMed         Abstract available
    
    
24. YUKSEL C, Dogan M, Culcu S, Dogan L, et al
    Can We Adapt Neoadjuvant Rectal (NAR) Score with Systemic Immune-Inflammation Index (SII) and Prognostic Nutritional Index (PNI) as Prognostic Factors in Locally Advanced Breast Cancer?
    Breast Cancer (Dove Med Press). 2026;18:578298.
    PubMed         Abstract available
    
    
25. YE R, Dai X, Yang Z, Zhang D, et al
    Clonal Dynamics and Molecular Heterogeneity of Metaplastic Breast Cancer: Focus on TP53 and PIK3CA Truncal Mutations.
    Breast Cancer (Dove Med Press). 2026;18:558033.
    PubMed         Abstract available
    
    
26. ZHANG Y, Li Q, Zhao L, Pang Y, et al
    Visceral and Subcutaneous Fat Deposits Exhibit Distinct Roles in the Initiation and Progression of Breast Cancer.
    Breast Cancer (Dove Med Press). 2026;18:565061.
    PubMed         Abstract available
    
    

    
    Breast Cancer Res

27. HLADIK C, Elayapillai SP, Dogra S, Bruns M, et al
    Nanoluciferase-CD63 labeling reveals extracellular vesicle kinetics in a mouse intraductal model of ductal carcinoma in situ.
    Breast Cancer Res. 2026;28:52.
    PubMed         Abstract available
    
    
28. ZHANG N, Zhang J, Shao J, Huang Z, et al
    Mechanism of IL-4 mediated RPL19 promoting malignant progression in HER2 positive breast cancer.
    Breast Cancer Res. 2026 Feb 21. doi: 10.1186/s13058-026-02240.
    PubMed        
    
    
29. JITWATCHARAKOMOL T, Gokun Y, Daniel SJ, Mestres-Villanueva M, et al
    Outcomes of once daily and twice daily accelerated partial breast irradiation regimens in hormone receptor positive breast cancer: a single institution experience.
    Breast Cancer Res. 2026 Feb 23. doi: 10.1186/s13058-026-02243.
    PubMed         Abstract available
    
    
30. DE GRUIL N, de Groot AF, Wesseling-Rozendaal Y, Keizer D, et al
    Pathway activity profiling can predict neoadjuvant endocrine therapy response in HR+ HER2- postmenopausal early stage breast cancer.
    Breast Cancer Res. 2026 Feb 25. doi: 10.1186/s13058-026-02245.
    PubMed        
    
    
31. CHEN J, Ma L, Yin M, Sun J, et al
    FBR-NDs: a ferroptosis-inducing nanocomplex for targeted breast cancer therapy via immune modulation and redox-responsive drug delivery.
    Breast Cancer Res. 2026 Feb 26. doi: 10.1186/s13058-026-02247.
    PubMed         Abstract available
    
    

    
    Breast Cancer Res Treat

32. DROZD C, Curtit E, Jacquinot Q, Roux P, et al
    Effect of a supervised intermittent exercise program on insomnia in breast cancer patients undergoing chemotherapy.
    Breast Cancer Res Treat. 2026;216:20.
    PubMed         Abstract available
    
    
33. TAGHIAN AJ, Aggarwal M, Shui AM, O'Donnell K, et al
    Baseline and early postoperative bioimpedance spectroscopy and perometry measurements in patients treated for breast cancer: insights from a prospective screening program.
    Breast Cancer Res Treat. 2026;216:19.
    PubMed         Abstract available
    
    
34. SISCA L, Polito MG, Silletta M, La Cesa A, et al
    Prognostic significance of circulating tumor DNA in early breast cancer: a systematic review and meta-analysis.
    Breast Cancer Res Treat. 2026;216:16.
    PubMed         Abstract available
    
    
35. HENRY NL, Monkman LK, Griffith K, Scheu K, et al
    Ovarian function suppression decision-making and uptake in premenopausal women with breast cancer: a mixed methods analysis.
    Breast Cancer Res Treat. 2026;216:17.
    PubMed         Abstract available
    
    
36. STERPI M, Dreyfus N, Lo Y, Fineberg S, et al
    Impact of immune-related adverse events on response to neoadjuvant chemoimmunotherapy in triple-negative breast cancer: a single-institution retrospective study.
    Breast Cancer Res Treat. 2026;216:18.
    PubMed         Abstract available
    
    
37. HUBER E, Gupta GP, Morse R, Abdou Y, et al
    Investigating initial patterns of progression on first-line treatment in patients with de novo metastatic breast cancer.
    Breast Cancer Res Treat. 2026;216:15.
    PubMed         Abstract available
    
    

    
    Breast J

38. DEN J, Nelson N, Vaghjiani R, Tyler D, et al
    Rising Breast Cancer Incidence and Poor Outcomes in Young Women: A Retrospective Study.
    Breast J. 2026;2026:5584726.
    PubMed         Abstract available
    
    
39. ALGHAMDI MA, Deshpande H, Maksoud WMAE, Amri FSA, et al
    Axillary Recurrence After a Negative Sentinel Lymph Node Biopsy (SLNB) for Initial Positive Node Breast Cancer Postneoadjuvant Therapy: Insights From a Systematic Review and Meta-Analysis.
    Breast J. 2026;2026:8396104.
    PubMed         Abstract available
    
    

    
    Cancer

40. REESE JB, Zimmaro LA, Sorice KA, Zhang L, et al
    Efficacy of a sexual quality of life intervention for couples facing metastatic breast cancer: Results of a randomized controlled trial.
    Cancer. 2026;132:e70334.
    PubMed         Abstract available
    
    
41. MONROY-IGLESIAS MJ, O'Connell K, Bhimani J, Blinder VS, et al
    Initial chemotherapy dose reductions and subsequent treatment delivery in stage I-IIIA breast cancer.
    Cancer. 2026;132:e70294.
    PubMed         Abstract available
    
    

    
    Cancer Lett

42. HAUSMANN F, Kobayashi T, Maggs L, Meyer MN, et al
    Antimetastatic activity of B7-H3-targeted CAR T-cell therapy in triple-negative breast cancer.
    Cancer Lett. 2026;644:218345.
    PubMed        
    
    
43. VERMA S, Singh V, Lang JE, Gupta S, et al
    Reprogramming the immune microenvironment in triple-negative breast cancer with mRNA therapeutics.
    Cancer Lett. 2026;645:218350.
    PubMed         Abstract available
    
    
44. WU CS, Chen HF, Huynh KT, Huang WC, et al
    Targeting PCK1 to overcome CDK4/6 inhibitor resistance for breast cancer therapy.
    Cancer Lett. 2026 Feb 24:218349. doi: 10.1016/j.canlet.2026.218349.
    PubMed         Abstract available
    
    

    
    Clin Breast Cancer

45. LIU Z, Guo S, Xu X, Tang P, et al
    A Venous Thromboembolism-Associated Model for Predicting Tumor Microenvironment Features in Breast Cancer.
    Clin Breast Cancer. 2026;26:102-118.
    PubMed         Abstract available
    
    
46. FRIEHMANN T, Shpitzer H, Shemesh MD, Atar E, et al
    Hard and Soft MRI Signs of Nipple-Areolar Complex Involvement in Breast Cancer.
    Clin Breast Cancer. 2026;26:94-101.
    PubMed         Abstract available
    
    

    
    Eur J Surg Oncol

47. YAMAMOTO A, Asaoka M, Horimoto Y, Yamada A, et al
    Clinicopathological predictors of distant recurrence in breast cancer patients achieving pathological complete response after neoadjuvant chemotherapy.
    Eur J Surg Oncol. 2026;52:111508.
    PubMed         Abstract available
    
    

    
    Histopathology

48. D'ARRIGO C, Tuzlali S, Barroso-Sousa R, El Saghir NS, et al
    Real-world prevalence of PD-L1 positivity in early-stage/metastatic triple-negative breast cancer: primary results and pathology insights from the global retrospective observational VANESSA study.
    Histopathology. 2026 Feb 22. doi: 10.1111/his.70091.
    PubMed         Abstract available
    
    

    
    Int J Cancer

49. WELLER J, Katzendobler S, Thiele F, Riesberg A, et al
    Association of recurrence patterns and outcome with HR and HER2 status in patients with resected brain metastases from breast cancer.
    Int J Cancer. 2026 Feb 25. doi: 10.1002/ijc.70407.
    PubMed         Abstract available
    
    

    
    Int J Radiat Oncol Biol Phys

50. ZHENG SY, Huang JQ, Xie JR, Gan L, et al
    Ultra-hypofractionated whole breast irradiation and sequential tumor bed boost for early breast cancer (SHIFT): primary results of a multicentre, Phase 2 trial.
    Int J Radiat Oncol Biol Phys. 2026 Feb 25:S0360-3016(26)00416.
    PubMed         Abstract available
    
    

    
    J Natl Cancer Inst

51. WOOLPERT KM, Kjaersgaard A, Schapira L, Toft Sorensen H, et al
    Opioid use after breast cancer in Denmark: a nationwide study of social and clinical factors.
    J Natl Cancer Inst. 2026 Feb 25:djag052. doi: 10.1093.
    PubMed         Abstract available
    
    

    
    Lancet

52. HARADA-SHOJI N, Suzuki A, Ishida T, Yamamoto S, et al
    Cumulative incidence of advanced breast cancer in women aged 40-49 years in the Japan Strategic Anti-cancer Randomised Trial (J-START) of adjunctive ultrasonography: a prespecified secondary analysis.
    Lancet. 2026;407:784-793.
    PubMed         Abstract available
    
    

    
    N Engl J Med

53. RUGO HS
    Hitting the Mark - Individualizing Therapy for HER2-Positive Early-Stage Breast Cancer.
    N Engl J Med. 2026;394:918-920.
    PubMed        
    
    

    
    NPJ Breast Cancer

54. BAKHUIS CFJ, Gkekos L, van Diest PJ, van der Wall E, et al
    Trimester of diagnosis affects tumor characteristics and survival in breast cancer during pregnancy: first results from the STURGATE collaboration.
    NPJ Breast Cancer. 2026 Feb 21. doi: 10.1038/s41523-026-00918.
    PubMed         Abstract available
    
    
55. BRITTEN K, Lipsyc-Sharf M, Yang EH, McCloskey S, et al
    Socioeconomic disparities in long-term heart failure risk of trastuzumab with or without anthracyclines in early-stage breast cancer: a SEER-Medicare database analysis.
    NPJ Breast Cancer. 2026 Feb 25. doi: 10.1038/s41523-025-00883.
    PubMed         Abstract available
    
    
56. MOKBEL K, Weedon MN, Moye V, Ruth KS, et al
    No evidence for genotype-treatment interactions with breast cancer endocrine therapy adverse effects in UK Biobank.
    NPJ Breast Cancer. 2026 Feb 26. doi: 10.1038/s41523-026-00923.
    PubMed         Abstract available
    
    
57. DRAGANOV D, Han Z, Rana A, Bennett N, et al
    Author Correction: Ivermectin converts cold tumors hot and synergizes with immune checkpoint blockade for treatment of breast cancer.
    NPJ Breast Cancer. 2026;12:31.
    PubMed        
    
    
58. SAMMONS SL, Kuntz TM, DiLullo M, Morgan XC, et al
    The landscape of the intestinal microbiome among patients with newly diagnosed invasive breast cancer and ductal carcinoma in situ (DCIS).
    NPJ Breast Cancer. 2026 Feb 27. doi: 10.1038/s41523-026-00922.
    PubMed         Abstract available
    
    

    
    PLoS One

59. 
    Expression of Concern: Dietary Compound Isoliquiritigenin Inhibits Breast Cancer Neoangiogenesis via VEGF/VEGFR-2 Signaling Pathway.
    PLoS One. 2026;21:e0343779.
    PubMed        
    
    

    
    Radiology

60. FUCHSJAGER MH, Adelsmayr G
    Background Parenchymal Enhancement and Race: An Emerging MRI Breast Cancer Risk Predictor.
    Radiology. 2026;318:e254037.
    PubMed        
    
    

    
    Radiother Oncol

61. SHAH I, Lucas S, Walsh R, Osman I, et al
    Artificial intelligence model for cardiovascular disease risk prediction in breast cancer patients using electronic health records and computed tomography scans.
    Radiother Oncol. 2026 Feb 25:111455. doi: 10.1016/j.radonc.2026.111455.
    PubMed         Abstract available
    
    
62. ALKNER S, Appelgren M, Szulkin R, Wieslander E, et al
    Association between shoulder joint radiation dose and arm morbidity in the randomized breast cancer trial SENOMAC.
    Radiother Oncol. 2026;218:111454.
    PubMed         Abstract available
    
    

    
    Semin Oncol

63. MARTIN-QUESADA AI, Martin-Abreu C
    Advances in the management of metastatic lobular breast cancer: Current evidence and emerging treatments.
    Semin Oncol. 2026;53:152466.
    PubMed         Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Breast Cancer is free of charge. Privacy / Datenschutzerklärung | Imprint / Impressum